Neil Torbett, an oncology expert, has been named chief executive of PhoreMost Ltd, a UK-based biopharmaceutical company. He was previously chief business officer and chief operating officer before being promoted to the position of CEO. He replaces Chris Torrance, the company’s founder, who will chair the board of directors. Dr Torbett joined PhoreMost in 2017 from Activiomics Ltd, a proteomics company that he co-founded and which was acquired by Retroscreen Virology in 2014. PhoreMost was founded that same year to develop screening technology for discovering new drug targets. It is currently building a pipeline of drug discovery programmes.
PhoreMost announced the appointment on 1 March 2022.
Copyright 2022 Evernow Publishing Ltd